Oncology · Acute Myeloid LeukemiaTrial Updateclinicalmid-term

Phase I Trial of 8-Chloroadenosine and Venetoclax in Relapsed/Refractory AML

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 12:30:58 AM

Assessment confidence: 77% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase I trial of 8-chloroadenosine in combination with venetoclax represents a potential breakthrough in the treatment of relapsed/refractory acute myeloid leukemia. Success in this trial could significantly alter treatment paradigms and competitive dynamics in the oncology landscape. Regulatory context from FDA (FDA AP — VENETOCLAX (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (13 high-relevance).

Strategic Assessment

If successful, this combination could provide a new treatment pathway, impacting market dynamics and positioning for both City of Hope and NCI. The strongest clinical anchor is 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia (ClinicalTrials.gov), entity match (8-chloroadenosine); patient population match (refractory). In Oncology · Acute Myeloid Leukemia, 2 regulatory and 5 competitive items passed relevance filtering for 8-Chloroadenosine.

Competitive Pressure

Secondary pressure from Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — VENETOCLAX (ORIG) (FDA). Entity match (venetoclax). Positive trial outcomes may facilitate expedited regulatory pathways, impacting approval timelines and market entry for this novel combination therapy.

Key Risks

Elevated medium regulatory exposure for 8-Chloroadenosine could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates safety and efficacy, it could lead to a new treatment option, potentially increasing market share for the involved entities and reshaping competitive positioning in the AML market.
Upside for 8-Chloroadenosine may improve if 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia (ClinicalTrials.gov) delivers favorable follow-through.
Upside for 8-Chloroadenosine may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
Upside for 8-Chloroadenosine may improve if Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (ClinicalTrials.gov) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy outcomes, as well as potential regulatory developments.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — VENETOCLAX (ORIG)
FDAhigh relevance
Entity match (venetoclax)
FDA document
View source
FDA AP — VENETOCLAX (ORIG)
FDAhigh relevance
Entity match (venetoclax)
FDA document
View source

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
ClinicalTrials.govhigh relevance
Entity match (8-chloroadenosine); Patient population match (refractory)
FDA document
View source
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic L
ClinicalTrials.govhigh relevance
Entity match (venetoclax); Patient population match (refractory)
FDA document
View source
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (refractory)
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (refractory)
FDA document
View source
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
ClinicalTrials.govhigh relevance
Entity match (venetoclax); Patient population match (refractory)
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Entity match (venetoclax)
FDA document
View source
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Entity match (venetoclax)
FDA document
View source
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients
Humanexa Signalshigh relevance
Entity match (venetoclax)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Phase II Trial of Lutetium Lu 177 Dotatate in Advanced Bronchial Neuroendocrine Tumors
Humanexa Signalsmedium relevance
Moderate corpus alignment
NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

8-Chloroadenosine
Venetoclax
National Cancer Institute

Commercial impact

medium

If the trial demonstrates safety and efficacy, it could lead to a new treatment option, potentially increasing market share for the involved entities and reshaping competitive positioning in the AML market.

Regulatory impact

medium

Positive trial outcomes may facilitate expedited regulatory pathways, impacting approval timelines and market entry for this novel combination therapy.

What to watch

Monitor trial results for safety and efficacy outcomes, as well as potential regulatory developments.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.